BTC USD 60,354.3 Gold USD 1,739.83
Time now: Jun 1, 12:00 AM

Covid-19 Nak percaya kpd apa? Nak percaya kpd siapa?

akudotcom

Legendary Member
Top Poster #3
Joined
Jun 17, 2007
Messages
12,860
Reaction score
2,143
Points
201
As China Gives Vaccines to Other Countries but Not Its Elderly, Chinese Over 60 Ask: What About Me?
WASHINGTON - As China sends millions of coronavirus vaccine doses to countries it hopes to influence, citizens at home who are over 60 are asking “What about me?”

Their question spotlights Beijing policy divergence from many Western nations, where the public health push focuses on immunizing as many older adults as soon as possible because they are more likely to become sicker and require hospitalization than younger people.

Instead, China is focusing on immunizing people aged 18-59 who are at high risk and highly likely to spread the virus, said Wang Bin, China's National Health and Health Commission official on February 13.

And some provincial governments are not administering vaccines to seniors due to safety concerns, saying few older people have been included in clinical trial.

Another factor may be that China has largely contained the spread of new cases of domestic transmission. While protocols in China are similar to those in the U.S. and elsewhere, the government has devised a system of color-coded health status updates shown via cellphone. Combined with frequent temperature checks, widespread testing and nearly universal mask wearing, "they have done an amazing job of controlling the virus," Ali Mokdad, a professor of global health at the University of Washington and a former official with the international health program at the Centers for Disease Control and Prevention told NBC News.

This photo taken on Nov. 22, 2015, shows elderly women playing mahjong at a nursing home in Beijing.
Nonetheless, the over-60 cohort worries.

Wang, a retired doctor in Hebei province who did not want his full name and age used due to fear of government reprisal, told VOA, “The elderly should be among the vulnerable, sick and disabled who are first to get vaccinated. It is common sense. The government said the trials haven’t been done among people over 60 years old, but I don’t think it really makes sense.”

A study published by BMC Medicine shows that individuals age 60 years and older had about a 4-times greater risk of severe or fatal COVID-19 than younger people.

Lin, a retired teacher in Shanxi province, asked that his full name and age be withheld as protection against attracting official attention. He suggested the vaccine policy has less to do with public health than Beijing’s interest in its image.

Chinese Foreign Minister Wang Yi recently told the United Nations that in order to oppose "vaccine nationalism" and clear the "vaccine gap," China has initially decided to provide 10 million new coronavirus vaccines to the World Health Organization.

Many developing countries are counting on Chinese-developed vaccines as affordable and available options, and China’s foreign ministry on February 8 said it will provide them to 53 countries.

China will produce just about enough doses by year’s end to cover 70% of its 1.4 billion people, according to The Washington Post. But instead of keeping all its projected 2 billion doses at home, China has shipped millions of doses to developing nations and pledged hundreds of millions more.

“China is exporting the vaccines to foreign countries more out of concern for the global impact this would make,” Lin, the retired teacher, told VOA Mandarin. “I think, by doing so, China wants to alleviate international accusations against China.” The coronavirus was likely spreading unnoticed in Wuhan, China, in November 2019 before doctors began reporting cases a month later.

“Of course, it also wants to win over countries that already have good relations with China and to bring them closer,” said Lin.

China will donate coronavirus vaccines to three African countries and plans to “assist” another 38 developing countries with shots in the future, according to Bloomberg, quoting the Chinese embassy in Kenya.

China is also ready to consider “vaccine cooperation” with Central and Eastern European countries, according to Xinhua, China’s state-run news agency. Serbia has already received 1 million doses of a Chinese-developed coronavirus vaccine while Hungarian and Chinese vaccine developers are cooperating.

Some of the countries that have received Chinese-developed vaccines are inoculating medical personnel first, followed by citizens who are 60 and older. In Peru, the elderly are the group that is second in line after frontline medical workers for a vaccine developed by Chinese company Sinopharm, according to China Daily, a Chinese government-run newspaper. Third in line are people between the ages of 18 and 59.

In the Dominican Republic, people who are 60 and above are among the first to receive the vaccines, according to Xinhua.

Sun, a Tianjin city resident who wanted only one name used for safety, said some elderly people are very anxious because they don’t know when it’s their turn.

“Why don’t they administer the vaccines for the elderly and frail? Why young people first?” she asked.

Lin gave VOA what he thinks is the real reason. "When the pandemic is over, if the international community is really holding China accountable for causing the pandemic, China will say that it has assisted this country and that country. … China does not admit that the pandemic originated from China, but after all, it originated from Wuhan. China has a guilty conscience."
 
Sponsored Post

Mata_Pena

Super Active Member
Joined
Oct 22, 2008
Messages
5,246
Reaction score
1,783
Points
141
aduh...
otak aku memang tak boleh catch up apa yg korang semua sembang...
semuanya terer2

aku ambik teladan je lah apa yg aku rasa baik
Netizen mmg ramai pakar..
Bagi la ape isu pun. Nanti akan keluar semua pakar punya hujah.

Tapi setakat hujah sembang kat sosial media je lah.
Suruh buat tak reti
 

akudotcom

Legendary Member
Top Poster #3
Joined
Jun 17, 2007
Messages
12,860
Reaction score
2,143
Points
201
Covid: What do we know about China's coronavirus vaccines?
14 January
Various medical syringes seen with Sinovac Biotech company logo displayed on a screen in the background.
Getty Images
Sinovac is a Beijing-based pharmaceutical company
As the global race to produce a Covid-19 vaccine continues, China appears to have made huge strides, with vaccines from two front-runners - Sinovac and Sinopharm - already making their way abroad.
But what do we know about China's vaccines and how do they compare to those being developed elsewhere?


How does the Sinovac vaccine work?


The Beijing-based biopharmaceutical company Sinovac is behind the CoronaVac, an inactivated vaccine.
It works by using killed viral particles to expose the body's immune system to the virus without risking a serious disease response.
By comparison the Moderna and Pfizer vaccines being developed in the West are mRNA vaccines. This means part of the coronavirus' genetic code is injected into the body, triggering the body to begin making viral proteins, but not the whole virus, which is enough to train the immune system to attack.
"CoronaVac is a more traditional method [of vaccine] that is successfully used in many well known vaccines like rabies," Associate Prof Luo Dahai of the Nanyang Technological University told the BBC.
"mRNA vaccines are a new type of vaccine and there is [currently] no successful example [of them] being used in the population," Prof Luo adds.
How will the new Pfizer vaccine work?
On paper, one of Sinovac's main advantages is that it can be stored in a standard refrigerator at 2-8 degrees Celsius, like the Oxford vaccine, which is made from a genetically engineered virus that causes the common cold in chimpanzees.
Moderna's vaccine needs to be stored at -20C and Pfizer's vaccine at -70C.
It means that both Sinovac and the Oxford-AstraZeneca vaccine are a lot more useful to developing countries which might not be able to store large amounts of vaccine at such low temperatures.


How effective is it?


It's hard to say at this point in time.
One Chinese study published in scientific journal The Lancet, only has information from the first and second phase trials of CoronaVac in China.
Zhu Fengcai, one of the paper's authors, said those results - based on 144 participants in the phase one trial and 600 in the phase two trial - meant the vaccine was "suitable for emergency use".
CoronaVac has been undergoing phase three trials in various countries. Interim data from late-stage trials in Turkey and Indonesia showed that the vaccine was 91.25% and 65.3% effective respectively.
Researchers in Brazil initially said it was 78% effective in their clinical trials, but in January 2021 revised that figure to 50.4% after including more data in their calculations. Earlier in November, their trials were briefly halted after the reported death of a volunteer, but resumed after the death was found to have no links to the vaccine.

Sinovac has been approved for emergency use in high-risk groups in China since July.
In September, Mr Yin of Sinovac said tests were performed on more than 1,000 volunteers, of which "some only showed minor fatigue or discomfort… no more than 5%".
Getty Images
Sao Paolo officials were photographed with the CoronaVac vaccine earlier this month
Prof Luo had said ahead of the phase three results that it was difficult to make comments about the vaccine's efficacy at that point in time "given the limited information available".
"Based on the preliminary data... CoronaVac is likely an effective vaccine, but we do need to wait for the results of the phase three trials," he said.
"These trials are randomised, observer-blind, placebo-controlled... with thousands of participants. This is the only way to prove a vaccine is safe and effective to be used at the population level."


What about the Sinopharm vaccine?


Sinopharm, a Chinese state-owned company, is developing two Covid-19 vaccines, which, like Sinovac are also inactivated vaccines that work in a similar way.
Sinopharm announced on 30 December that phase three trials of the vaccine showed that it was 79% effective - lower than that of Pfizer and Moderna.
However, the United Arab Emirates, which approved a Sinopharm vaccine earlier this month, said the vaccine was 86% effective, according to interim results of its phase three trial
.
Getty Images
Both the UAE and Bahrain have granted emergency use of the vaccine on frontline workers
A company spokeswoman declined to explain the discrepancy, and said detailed results would be released later, said a Reuters report.
But even ahead of the phase three trial results, the vaccine had already been distributed to nearly a million people in China under an emergency programme.
Professor Dale Fisher, of the National University of Singapore, said then that it was "unconventional" to ramp up a vaccine programme without first going through last stage trials.
"It is normal to wait for an analysis of phase three trials before ramping up a vaccine programme through emergency use authorisation," he told news site CNBC.
Earlier in December, Peru suspended trials for the Sinopharm vaccine due to a "serious adverse event" affecting a volunteer. It later said that it lifted the suspension.
A pause in a clinical trial is not unusual. In September, the UK paused trials for another Covid-19 vaccine after a participant had a suspected adverse reaction, resuming after the vaccine was ruled out as the cause.
The spread of the coronavirus within China has for the most part been contained - and life is slowly but surely returning to a "new normal".


Any other vaccine candidates?


At least two other Covid-19 vaccines are under development in China, according to a recent article in The Conversation.
One of them is CanSino Biologics, which is reportedly in phase three clinical trials in countries including Saudi Arabia.
The other is being developed by Anhui Zhifei Longcom. Its vaccine uses a purified piece of the virus to trigger an immune response, and has recently entered phase three trials, according to the report.


Which countries are signing up for China's vaccines?


Several Asian countries including Singapore, Malaysia and the Philippines have signed deals with Sinovac, and in January 2021 Indonesia began rolling out its mass vaccination campaign with their vaccine.
Turkey has also approved the Sinovac vaccine for emergency use. The company is also known to have secured other deals with Brazil and Chile.
The United Arab Emirates and Bahrain have approved the Sinopharm vaccine.


How would rollout work for China's vaccines?


Sinovac will be able to produce 300 million doses a year in its newly built 20,000 sq m production plant, its chairman told state media outlet CGTN.
Like all the other vaccines, it requires two doses, which means it is currently only able to inoculate 150m people a year - just over a tenth of China's population.
Analysts point to China's bid to win the vaccine diplomacy race, which has also reportedly seen China's President Xi Jinping pledge to set aside $2bn for the African continent, while also offering Latin American and Caribbean countries a $1bn loan to buy vaccines. It's unclear what the terms of such a deal might be.
"Beijing... will surely leverage the provision of this life-saving technology for commercial and diplomatic profit," Jacob Mardell, an analyst from MERICS, told ABC news.
"[It] possesses something countries dearly need and will seek to paint the vaccine's provision as an act of charity."
It's not clear how much it might cost, but earlier this year, a BBC team in the Chinese city of Yiwu saw that nurses were administering the injections for a fee of around 400 yuan ($60; £45).
Hundreds of people queued in Yiwu, China to get an experimental Covid-19 vaccine
Bio Farma, a state-owned firm in Indonesia said it would cost around 200,000 rupiah ($13.60; £10) locally.
That is still far higher than the Oxford vaccine, which costs $4 a dose, but lower than Moderna's at $33 per dose. Moderna has said it aims to ship 500 million doses in 2021 and AstraZeneca has said it will produce 700 million doses by the end of the first quarter of 2021.
 

akudotcom

Legendary Member
Top Poster #3
Joined
Jun 17, 2007
Messages
12,860
Reaction score
2,143
Points
201
Apa yg sy lihat dlm forum ni
Dia yg ramai pakar sondol
Dia sendiri bukan pakar pun
Yg dia tau ko ada degree apa :D
 

konaLeper

Fun Poster
Joined
Dec 22, 2016
Messages
198
Reaction score
46
Points
30
Strategi vs Konspirasi?

Matlamat strategi kebiasaannya tak menyalahi undang2/norma kemanusian/dll sementara matlamat konspirasi di sebaliknya.

Nak ambil sbg contoh 9/11, tak cukup maklumat. Kita ambil contoh yg lebih dekat dan konkrit iaitu langkah sheraton.

Bg penyokong PN, ianya strategi (the grandmaster strategist)
Bg penyokong PH, ianya konspirasi (conspiracy theorist).
Bg yg atas pagar, agaknya malas nak fikir, ianya kebetulan (coincidence theorist).

Label mana 1 nak pakai:
The grandmaster strategist atau the greatest conspirator?
Conspiracy theorist (yg tak malas nak guna akal) atau coincidence theorist (yg malas nak guna akal)?

Yg aku baca, istilah conspiracy theory dicipta oleh CIA bagi meremeh/meleceh mereka yg percaya berlaku konspirasi peringkat tertinggi.

The CIA created the term “conspiracy theorist” in April 1967. It first appeared in a CIA dispatch marked “psych” – for “psychological operations” — and was created for the purpose of disparaging those people who believe that a high-level conspiracy is taking place.

Pada aku, teori konspirasi yg gila2 tanpa disertakan bukti yg munsabah dan tak boleh berdiri tegak dlm mahkamah, mmg patutpun ditolak. Kebarangkalian ianya ciptaan ejen2 cia bg mengeruhkan keadaan pun bukan perkara yg mustahil.
Mana2 yg tak sealiran dgn naratif umum dan ditolak sbg teori konspirasi adalah pegangan yg kurang rasional.

Jgn mulut kata benci tapi tak sedar terjerat dgn propaganda cia. Aku hanya mengingatkan diri aku sendiri shj dlm hal ini.
 

shah_ae

Legendary Member
Joined
Oct 27, 2008
Messages
15,495
Reaction score
652
Points
161
Tggu tarikh nak suntik je...
Anggap mcm suntik vaksin2 mase zaman sekolah...
Semoga Allah melindungi kite semua...
 

akudotcom

Legendary Member
Top Poster #3
Joined
Jun 17, 2007
Messages
12,860
Reaction score
2,143
Points
201
Kenyataan Akhbar KPK 2 Mac 2021 – Keputusan Mesyuarat Pihak Berkuasa Kawalan Dadah Kali ke-354 Berkenaan Pendaftaran Vaksin COVID-19

Kementerian Kesihatan ingin memaklumkan bahawa Mesyuarat Pihak Berkuasa Kawalan Dadah (PBKD) kali ke-354 telah bersidang pada hari ini, 2 Mac 2021. Mesyuarat telah bersetuju meluluskan pendaftaran secara bersyarat untuk kegunaan semasa bencana bagi produk vaksin COVID-19 berikut:

COVID-19 Vaccine AstraZeneca Solution for Injection
- Pemegang: AstraZeneca Sdn. Bhd.
- Pengilang: Medimmune Pharma B.V. Netherland

CoronaVac Suspension for Injection – Sinovac
- Pemegang pendaftaran: Pharmaniaga Lifescience Sdn. Bhd.
- Pengilang: Sinovac Life Sciences Co. Ltd., China

COMIRNATY Concentrate for Dispersion for Injection (Permohonan bagi sumber kedua kepada produk COMIRNATY yang telah diberikan pendaftaran bersyarat)
- Pemegang pendaftaran: Pfizer (M) Sdn. Bhd.
- Pengilang bagi sumber pertama (drug product and final release): Pfizer Manufacturing Belgium NV, Puurs, Belgium
- Pengilang bagi sumber kedua (final release): BioNTech Manufacturing GmbH, Mainz, Germany

Pendaftaran secara bersyarat ini memerlukan syarikat pemegang pendaftaran untuk mengemukakan analisis data-data tambahan dan terkini secara rolling submission untuk dinilai oleh Bahagian Regulatori Farmasi Negara (NPRA). Ia bagi memastikan keberkesanan dan keselamatan vaksin sentiasa dikemaskini dan perbandingan manfaat-risiko (benefit over risk) vaksin ini kekal positif.

Pada masa ini, NPRA juga masih menilai 2 lagi produk vaksin COVID-19 iaitu Gam-COVID-Vac atau Sputnik V (keluaran Gamaleya National Research Centre for Epidemiology and Microbiology, Russia) dan CoronaVac Suspension for Injection – Sinovac (pengilangan fill and finish oleh Pharmaniaga LifeScience Sdn Bhd).

Kementerian Kesihatan akan sentiasa mempertingkatkan tahap kesihatan awam dalam memerangi wabak COVID-19 melalui perolehan bekalan vaksin yang telah dinilai daripada aspek kualiti, keselamatan dan keberkesanan oleh Bahagian Regulatori Farmasi Negara (NPRA) dan diluluskan oleh PBKD. Kerajaan juga komited untuk memastikan penduduk dewasa Malaysia mencapai imuniti kelompok (herd immunity) selaras dengan sasaran Program Imunisasi Vaksin COVID-19 Kebangsaan.

 
Sponsored Post

CG Sponsors




Top
Log in Register